Related Experiment Video
Updated: May 12, 2026

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
Published on: March 3, 2023
Linezolid in late-chronic prosthetic joint infection caused by gram-positive bacteria
Javier Cobo1, Jaime Lora-Tamayo, Gorane Euba
1Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain. jcobo.hrc@salud.madrid.org
Abstract:
Linezolid may be an interesting alternative for prosthetic joint infection (PJI) due to its bioavailability and its antimicrobial spectrum. However, experience in this setting is scarce. The aim of the study was to assess linezolid's clinical and microbiological efficacy, and also its tolerance. This was a prospective, multicenter, open-label, non-comparative study of 25 patients with late-chronic PJI caused by Gram-positive bacteria managed with a two-step exchange procedure plus 6 weeks of linezolid. Twenty-two (88%) patients tolerated linezolid without major adverse effects, although a global decrease in the platelet count was observed. Three patients were withdrawn because of major toxicity, which reversed after linezolid stoppage. Among patients who completed treatment, 19 (86%) demonstrated clinical and microbiological cure. Two patients presented with clinical and microbiological failure, and one showed clinical cure and microbiological failure. In conclusion, linezolid showed good results in chronic PJI managed with a two-step exchange procedure. Tolerance seems acceptable, though close surveillance is required.
Insights
Linezolid offers a promising treatment for prosthetic joint infections (PJI) when combined with surgical exchange. This study found it effective and generally well-tolerated, though platelet count monitoring is crucial.
Area of Science:
- Infectious Diseases
- Orthopedic Surgery
- Pharmacology
Background:
- Prosthetic joint infection (PJI) is a challenging complication requiring effective antimicrobial therapy.
- Limited clinical data exists on linezolid's efficacy and safety for PJI.
- Linezolid's pharmacokinetic profile suggests potential utility in PJI treatment.
Purpose of the Study:
- To evaluate the clinical and microbiological efficacy of linezolid in patients with chronic PJI.
- To assess the safety and tolerance of linezolid in this patient population.
- To determine the cure rate of linezolid combined with a two-step exchange procedure for Gram-positive PJI.
Main Methods:
- Prospective, multicenter, open-label, non-comparative study.
- Involved 25 patients with late-chronic PJI caused by Gram-positive bacteria.
- Treatment consisted of a two-step exchange procedure followed by 6 weeks of linezolid.
Main Results:
- 88% of patients tolerated linezolid; 12% experienced toxicity requiring withdrawal.
- A decrease in platelet count was a common adverse effect.
- 86% of patients achieved clinical and microbiological cure after completing linezolid treatment.
Conclusions:
- Linezolid demonstrates good clinical and microbiological outcomes for chronic PJI when used with a two-step exchange procedure.
- Linezolid's tolerance is acceptable, but requires vigilant monitoring for adverse effects, particularly thrombocytopenia.
- Further research may explore linezolid's role in PJI management, optimizing its use and safety profile.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Clinical Significance of Antibiotic Resistance
Endocarditis III: Medical Management
Staphylococcal Skin Infections
Inhibitors of Gram-positive Cell Wall Synthesis
Endocarditis IV: Nursing Management
